12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Kuvan: Phase III data

The double-blind, North American Phase III PKU-016 ASCEND trial in 206 patients showed that 20 mg/kg/day oral Kuvan missed the primary endpoint of reducing ADHD-RS score from baseline to week 13 vs. placebo (9.5 vs. 5.4 points, p=0.085). BioMarin said ADHD-RS scores are commonly used to evaluate symptoms of inattentiveness and hyperactivity. Kuvan did significantly reduce the inattentiveness component of the ADHD-RS score from baseline to week 13 vs. placebo (6 vs....

Read the full 336 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >